HISUN(SH:600267) Xin Lang Cai Jing·2025-10-09 17:18Group 1 - The core point of the article is the announcement by Zhejiang Haizheng Pharmaceutical Co., Ltd. regarding the progress of its fourth share repurchase plan through centralized bidding [1] Group 2 - The key information of the repurchase plan includes a total repurchase fund of no less than 50 million yuan and no more than 100 million yuan, with a maximum repurchase price of 13 yuan per share, and the repurchase period from May 12, 2025, to May 11, 2026 [2] Group 3 - As of the end of September 2025, the company has repurchased a total of 5.535 million shares, accounting for 0.46% of the total share capital, with an actual repurchase price range between 8.92 yuan and 9.40 yuan per share, totaling 50,891,385 yuan paid (excluding transaction fees) [3] - The company did not conduct any share repurchases in September 2025, but it stated that it will strictly follow relevant regulations and make repurchase decisions based on market conditions within the repurchase period [3]